Tumor Immunotherapy (TI1)

 Friday, May 6, 2022     2:00 PM – 4:00 PM ET     Oregon Ballroom 203

Tumor Immunotherapy (TI1)

Chairs

• Eduardo Davila, Univ. of Colorado
• Beth Tamburini, Univ. of Colorado Anschutz Med. Campus

Speakers

• Subir Biswas, Moffitt Cancer Ctr. and Res. Inst., CAR T cells targeting Olfactory Receptor OR2H1 are an effective immunotherapeutic option in human epithelial tumors
• Jiemiao Hu, MD Anderson Cancer Ctr., Cell membrane-anchored and tumor-targeted IL-12 (attIL12)-T cell therapy for eliminating large and heterogeneous solid tumors
• Colin J. Thalhofer, AgonOx Inc., Enriching for tumor-reactive CD8 TIL (AGX148) leads to effective tumor clearance in a patient-derived xenograph model
• Joey C. Magno, Univ. of Colorado Anschutz Med. Campus, A novel linked TCR:MyD88 receptor improves anti-tumor responses while maintaining antigen specificity
• Thomas Duhen, Earle A. Chiles Res. Inst., PD-1 and ICOS co-expression identifies tumor-reactive CD4 Th cells in human solid tumors
• Kathryn M. Laporte, Univ. of Miami, Targeting the high-affinity IL-2R with high-dose mIL-2/CD25 induces effective antitumor responses
• Silvia Guglietta, Med. Univ. of South Carolina, Complement downregulation promotes an inflammatory signature that renders colorectal cancer susceptible to immunotherapy
• Paramita Chakraborty, Med. Univ. of South Carolina, Targeting autophagy with carbon-monoxide reprograms anti-tumor t cells with robust immunometabolic phenotype